Both mRNA-1020 and mRNA-1030 target hemagglutinin and neuraminidase antigens, two major influenza surface glycoproteins that are essential across the viral life cycle
Results from pre-clinical research show iron-like compound hold promise for treating patients with glioblastoma, an aggressive brain cancer
Essent continues to broaden its highly characterized, low passage primary cell catalog
Veeda Clinical Research will submit data in an application for Emergency Use Authorisation
The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Pradaxa Capsules of Boehringer lngelheim
Immunocin, an Immuno-modulator drug, significantly reduced the risk of death in the Phase 3 clinical trial in adult patients with moderate-to-severe Covid-19
R&D investment up 11.7% to 4.1 billion EUR in 2021 (20.0% of net sales)
If approved, it will be the first USFDA-approved immunomodulator for the treatment of Covid-19 in hospitalised patients
Yescarta is First CAR T-cell therapy to receive NCCN treatment guideline category 1 recommendation --
Among patients with infectious virus at baseline, no patients who received Lagevrio had infectious virus at days 3, 5 or 10
Subscribe To Our Newsletter & Stay Updated
